| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Atara Biotherapeutics, Inc. (ATRA) has 3 insiders with recent SEC Form 4 filings, including 0 buys and 17 sells. ATRA is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 1.32M | $13.97M | - | |
| CEO | 143.1K | $1.51M | - | |
| Other | 52.0K | $549.1K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Aug 16, 2017 | McGrath John | EVP &Chief Financial Officer | Sale+OE | 4,200 | $14.31 | $60,102.00 | -1.7% | |
| Aug 16, 2017 | Clark Mitchall G. | EVP &Chief R &Qa Officer | Sale+OE | 3,021 | $14.33 | $43,290.93 | -1.9% | |
| Aug 15, 2017 | Haqq Christopher | EVP, R&D &Chief Scientific Of | Sale+OE | 7,604 | $14.75 | $112,159.00 | -2.1% | |
| Aug 11, 2017 | Ciechanover Isaac E. | Chief Executive Officer | Sell | 4,400 | $14.67 | $64,526.00 | -0.5% | |
| Jul 25, 2017 | Ciechanover Isaac E. | Chief Executive Officer | Sell | 5,500 | $16.49 | $90,704.00 | -0.3% | |
| Jul 17, 2017 | Haqq Christopher | EVP, R&D &Chief Scientific Of | Sell | 6,000 | $14.92 | $89,520.00 | -1.6% | |
| Jun 15, 2017 | Haqq Christopher | EVP, R&D &Chief Scientific Of | Sell | 6,000 | $12.65 | $75,900.00 | -1.6% | |
| Jun 9, 2017 | Gallagher Carol Giltner | Director | Sell | 1,000 | $13.15 | $13,150.00 | -0.9% | |
| May 31, 2017 | Ciechanover Isaac E. | Chief Executive Officer | Sell | 6,900 | $13.35 | $92,115.00 | -0.7% | |
| May 18, 2017 | Ciechanover Isaac E. | Chief Executive Officer | Sell | 4,800 | $14.91 | $71,568.00 | -0.5% |